Thursday, September 13, 2012
Existing tests to screen patients for
tuberculosis are impractical in the point-of-care setting as they are either
too slow, lack sensitivity or require specialized lab equipment.1,2
Researchers at Stanford University and Texas A&M University have synthesized highly sensitive class A b-lactamase-specific fluorogenic probes that could potentially
address all three shortcomings.3 Global BioDiagnostics Corp. has in-licensed the technology.
Optimizing TB diagnosis
Built to test
Lou, K.-J. SciBX 5(36);
Published online Sept. 13, 2012
1. McNerney, R. &
Daley, P. Nat.
Rev. Microbiol. 9, 204-213 (2011)
2. Pinto, L.M. et al. Med. Princ.
Pract. 21, 4-13 (2012)
3. Xie, H. et al. Nat. Chem.; published online Sept. 2, 2012;
Contact: Jianghong Rao, Stanford University, Stanford, Calif.
4. Kong, Y. et al. Proc. Natl.
Acad. Sci. USA 107, 12239-12244 (2010)
AND INSTITUTIONS MENTIONED
Bill & Melinda Gates Foundation, Seattle, Wash.
Cepheid Inc. (NASDAQ:CPHD), Sunnyvale, Calif.
FIND (Foundation for Innovative New Diagnostics), Geneva, Switzerland
Global BioDiagnostics Corp., Temple, Texas
Harvard Medical School, Boston, Mass.
Massachusetts General Hospital, Boston, Mass.
McGill University, Montreal, Quebec, Canada
Research Valley Funds LLC, College Station, Texas
Stanford University, Stanford, Calif.
Texas A&M Health Science Center, Bryan, Texas
Texas A&M University, College Station, Texas
World Health Organization, Geneva, Switzerland